olfactory receptor family 2 subfamily L member 9 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR2L9P profile across patient tissues and cancer cell-line models. OR2L9P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR2L9P is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, OR2L9P RNA expression shows 8,927 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight STAD, THCA, and LAML as cancer lineages where OR2L9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2L9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2L9P survival associations across molecular data types. OR2L9P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2L9P RNA expression–survival associations across cancer types. High OR2L9P expression shows unfavorable associations in STAD, MESO, PAAD, UVM, COAD and SARC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for OR2L9P RNA expression.
This table summarizes OR2L9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR2L9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2L9P shows lower tumor expression in THCA. The THCA box plot shows higher OR2L9P RNA expression in normal versus tumor tissue (log2 FC = −0.026, t-test p = .017).
This table shows molecular features associated with OR2L9P in patient tissues and cancer cell lines. In patient samples, OR2L9P shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
